Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib plus weekly paclitaxel versus weekly paclitaxel in platinum-resistant or refractory ovarian cancer
2009-016151-21Phase 2Completed
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Dec 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in ovarian cancer comparing Pazopanib + weekly paclitaxel with Weekly paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Dec 2009; status: completed.
02
Drugs
pazopanibpaclitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2009-016151-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016151-21.